PG
AEGR

PEAK6 Group’s Aegerion Pharmaceuticals AEGR Stock Holding History

PEAK6 Group’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-10,000
Closed -$136K – 5731
2015
Q3 		$136K Buy
+10,000
New +$178K ﹤0.01% 4086
2015
Q2 		– Sell
-70,000
Closed -$1.83M – 5820
2015
Q1 		$1.83M Buy
70,000
+20,000
+40% +$509K 0.01% 1353
2014
Q4 		$1.05M Buy
+50,000
New +$1.26M 0.01% 1911
2014
Q2 		– Sell
-4,500
Closed -$208K – 5506
2014
Q1 		$208K Buy
+4,500
New +$264K ﹤0.01% 3397

Other funds holding AEGR

ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

PEAK6 Group's AEGR Position: Q2 2015 in Review

PEAK6 Group sold out of Aegerion Pharmaceuticals (AEGR) in Q2 2015, closing a stake of 17,736 shares — an estimated $464K sold.

PEAK6 Group first reported a position in AEGR in Q1 2014 and held it in 3 quarters. The position peaked at $655K in Q4 2014. 97 funds tracked by Wall St. Rank hold AEGR as of Q2 2015.

  • PEAK6 Group reported no remaining Aegerion Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • PEAK6 Group sold 17,736 Aegerion Pharmaceuticals shares in Q2 2015, an estimated $464K.
  • PEAK6 Group first reported a position in Aegerion Pharmaceuticals in Q1 2014 and held it in 3 quarters.
  • PEAK6 Group's Aegerion Pharmaceuticals position peaked at $655K in Q4 2014.
  • 97 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q2 2015.

Based on PEAK6 Group's 13F filing for Q2 2015, filed 11 Aug 2015.